1 Prescribing patterns for medical treatment of suspected prostatic obstruction: A
2 spatiotemporal statistical analysis of Scottish open access data

3 **Authors**

4 Federico Andreis, PhD [Faculty of Health Sciences and Sport, University of Stirling]

5 Richard Bryant, BMedSci MBChB FRCSEd(Urol) PHD [Nuffield Department of
6 Surgical Sciences, University of Oxford, Oxford Cancer Research Centre, Oxford] &
7 [Department of Urology, Churchill Hospital, Oxford University Hospitals NHS
8 Foundation Trust]

9 Emanuele Giorgi, PhD [Lancaster Medical School, University of Lancaster]

10 Andrea Williamson, MBChB MPH PhD FRCGP FHEA DTM&H [General Practice and
11 Primary Care, School of Medicine, Dentistry and Nursing, MVLS, University of
12 Glasgow] & [General Practitioner Homelessness Health, Medical Officer Addictions,
13 NHS Glasgow and Clyde, Homeless Health and Resource Services]

14 Ashleigh Ward, PhD [Faculty of Health Sciences and Sport, University of Stirling]

15 **Corresponding author**

16 Federico Andreis, PhD

17 Faculty of Health Sciences and Sport, Pathfoot Building, University of Stirling, FK9
18 4LA, Stirling

19 email: federico.andreis@stir.ac.uk

20 tel: +44(0)1786466252

21 **Word count** 3790 (abstract: 277 / text: 3513, excl. figures, tables, equations and
22 captions)

23 **Abstract**

24 **Background** Healthcare services treating men with prostate conditions are
 25 increasingly burdened worldwide. One of the competing factors in this demand is
 26 increasing diagnosis and treatment of lower urinary tract symptoms in men, much of
 27 which is suspected bladder outflow obstruction secondary to benign prostate
 28 hyperplasia/enlargement. However, the impact of increases on services is largely
 29 hidden, and there is limited knowledge of potential differences in management based
 30 on geography.

31 **Objective** To investigate potential variation in the prescribing of drugs for suspected
 32 bladder outflow obstruction in Scotland based on analysis of publicly available data,
 33 and identify trends that may help to inform future prescribing behaviour.

34 **Design, setting, and participants** We linked the relevant publicly available
 35 prescribing and patient data to all general practices in Scotland between October
 36 2015 and November 2019.

37 **Outcome measurements and statistical analysis** We analysed the numbers of
 38 daily doses of drugs prescribed for suspected bladder outflow obstruction per month
 39 using a Bayesian Poisson regression analysis, incorporating random effects to
 40 account for spatial and temporal elements in prescribing.

41 **Results** Prescriptions of drugs to treat suspected bladder outflow obstruction
 42 increased during the observation period in Scotland, consistent with an ageing
 43 population and increased diagnosis. Whilst some determinants of health inequality
 44 regarding prescribing practices across health boards are consistent with those
 45 known from the literature, other inequalities remain unexplained after accounting for

46 practice- and patient-specific characteristics such as socio-economic deprivation and
47 rurality.

48 **Conclusions** Variations in spatiotemporal prescribing for suspected bladder outflow
49 obstruction exist in Scotland, some of which are unexplained and require further
50 investigation.

51 **Keywords**

52 Suspected bladder outflow obstruction, benign prostate hyperplasia, benign prostate
53 enlargement, lower urinary tract symptoms, drug prescription, open access data,
54 spatiotemporal modelling, medical practice

55 Introduction

56 The incidence of bothersome lower urinary tract symptoms (LUTS) in men, which are
 57 predominantly attributable to benign prostate hyperplasia (BPH) and/or benign
 58 prostatic enlargement (BPE) causing proven or suspected bladder outflow
 59 obstruction (BOO), is increasing globally [1] resulting in a reduced quality of life and
 60 increased healthcare expenditures [1, 2]. In Scotland as elsewhere in the United
 61 Kingdom and globally, some men may be managed conservatively or medically
 62 using drugs in the primary care setting for suspected or proven BOO (referred
 63 hereafter as BOO), whilst other men may have received investigation in a secondary
 64 care setting, before being recommended to receive medication in primary care. In
 65 Scotland healthcare services treating men with prostate conditions face an
 66 increasing burden from combinations of an ageing population, increased prostate
 67 cancer investigation and incidence [3], and increased awareness of male health
 68 issues. As a result of these combined factors, the impact of bothersome LUTS
 69 arising from BOO on service demand is largely hidden, and studies reporting their
 70 incidence and prevalence are predominantly cross-sectional in nature, with widely
 71 varying results [5].

72 Data regarding the prescription of drugs for the medical management of BOO as a
 73 cause for male bothersome LUTS has been used internationally in recent years to
 74 increase the understanding of patterns of prescribing within specific populations.
 75 This approach can be useful in order to identify potential demographic inequalities in
 76 patient's access to this aspect of healthcare, and to understand the patient
 77 experience, predominantly using longitudinal datasets [6, 7, 8]. However, to date
 78 there is limited understanding of how the prescribing patterns for drugs used to
 79 medically treat BOO may differ both spatially and temporally. The increasing

80 availability of high-quality open access healthcare data in Scotland has created the
81 opportunity for a more refined and broader-based analysis of prescribing patterns for
82 BOO. Moreover, Scotland's diverse geography provides an ideal landscape to
83 understand how factors that may impact on prescribing patterns differ spatially in
84 terms of geography, as well as longitudinally [9]. We describe a statistical framework
85 that allows the study of variations in the patterns of drug prescribing in both space
86 and time, while accounting for numerous relevant socioeconomic and health-related
87 factors. We have used this approach in order to statistically analyse publicly
88 available data regarding the prescription of the two main classes of medications
89 used to treat bothersome LUTS secondary to BOO in Scotland. Using this approach,
90 we describe spatiotemporal trends that may help inform future urological practice for
91 this common and ubiquitous condition.

92 **Material and Methods**

93 Data sources

94 Data was acquired and linked from numerous independent and publicly accessible
95 sources. The dataset comprised information at the level of individual General
96 Practices (GPs) and was been created from the following four sources:

- 97 1. NHS Scotland OpenData: drug prescriptions monthly data
98 (<https://www.opendata.nhs.scot/dataset/prescriptions-in-the-community>)
- 99 2. Information Services Division Scotland (ISD): practice details, deprivation,
100 rurality (<https://www.isdscotland.org/Health-Topics/General-Practice/>)
- 101 3. National Institute for Health and Care Excellence (NICE): daily dosages
102 (<https://www.nice.org.uk>)
- 103 4. National Records of Scotland (NRS): postcodes, health boards
104 ([https://www.nrscotland.gov.uk/statistics-and-data/geography/our-](https://www.nrscotland.gov.uk/statistics-and-data/geography/our-products/scottish-postcode-directory/2018-2)
105 [products/scottish-postcode-directory/2018-2](https://www.nrscotland.gov.uk/statistics-and-data/geography/our-products/scottish-postcode-directory/2018-2))

106 The keys used to link the sources were the unique GP code and date. The ISD and
107 NRS portals provided information regarding both the medical practice (i.e. GP) and
108 their patient population. Table 1 contains a list of the variables extracted from these
109 sources. We used both socio-economic deprivation and rurality to account for socio-
110 demographic status. In particular, we used the 2016 Scottish Index of Multiple
111 Deprivation (SIMD) [10] and a recoded version of the 2018 Scottish Government
112 Urban Rural Classification [11]. Additionally, the ISD and NRS sources provided GP-
113 level information regarding the size of the individual practice patient list, the gender
114 and age distribution, and the location of the practice (based on postcode and name
115 of relevant Health Board). It is important to note that digital boundaries of Scottish

GP practice catchment areas are not available; as a consequence, the spatial reference for both the GP practice- and patient-level data is the GP practice address. All GP practices open for the whole study period (October 2015 to November 2019) were included in the dataset (903 of 944, 95.7%, practices in Scotland open as of 1st January 2019). The Scottish Open Data portal provided the prescribed amounts of the drugs of interest per month.

Table 1. Variables extracted from the four data sources and used as covariates in the statistical model.

Variable	Type	Short description
Drug group	Categorical	α -1 blocker or 5- α reductase inhibitor
GP patient list size	Numerical, time-varying	Number of registered patients per GP practice
GP practice run	Categorical, baseline	Is the practice run by GPs (contract type 17J and 17C), rather than by the NHS (contract type 2C)? Yes/No
Dispensing GP practice	Categorical, baseline	Does the GP practice have a license to dispense medicines? Yes/No
Males 45p	Numerical, time-varying	Proportion of patients that are males aged ≥ 45 years
Deprived 15	Numerical, time-varying	Proportion of patients under the 15 th national percentile of deprivation (SIMD)
Remote	Categorical, time-varying	Modal rurality index among the patients (Scottish Government 8-fold Urban Rural Classification) recoded as remote (4, 5, 7, 8) or non-remote (1, 2, 3, 6). Yes/No
Postcode	Categorical, baseline	GP practice postcode as of 2019
Health board	Categorical, baseline	Name of Scottish Health Board where the GP practice is situated.

BOO medications analysed

We specifically focussed on the prescribing of α -1 blocking drugs and 5- α reductase inhibitors as these are the only specific medications used for BOO. α -1 blockers are the first-line and most commonly used drugs prescribed for LUTS secondary to BOO [1, 12], whilst 5- α reductase inhibitors are generally recommended where men are considered at high risk of BPH progression due to a significantly enlarged prostate, either as monotherapy or in combination with α -1 blockers [1, 12, 13]. The α -1 blockers alfuzosin and tamsulosin hydrochloride were included in the study, however doxazosin and terazosin were not included as the amounts of these drugs prescribed

were negligible, whilst doxazosin may be prescribed for hypertension. The 5- α reductase inhibitors dutasteride and finasteride were both included in this study. When combined with the suggested daily dosages from the NICE website (see Table 2), a proxy for the number of daily doses was constructed by rounding to the nearest integer the following expression:

$$n_{dti} = \frac{\text{\#tablets of drug } d \text{ prescribed during month } t \text{ at practice } i}{\text{daily suggested dosage for drug } j} \#(1)$$

where i , d , and t represent the GP practice, drug, and month respectively. In our dataset, we have observations for $i = 1, \dots, 903$ GP practices over $t = 1, \dots, 50$ months; d indexes the drugs reported in Table 2. The number of daily doses for each of the drug groups was then constructed by summation of the respective drugs' monthly amounts of daily doses. We denote with n_{jti} the number of daily doses of drugs belonging to group $j \in \{\alpha 1 - \text{blocker}, 5 - \alpha \text{ reductase inhibitor}\}$, prescribed during month t , at each GP practice i .

Table 2. Suggested daily dosages of the study α -1 blockers and 5- α reductase inhibitors according to NICE guidelines.

Drug	Drug group	Suggested daily dosage (NICE)
Alfuzosin	α -1 blocker	2.5 mg 3 times a day
Tamsulosin cap/tab	α -1 blocker	10 mg once daily
Dutasteride	5- α reductase inhibitor	400mcg once daily
Finasteride	5- α reductase inhibitor	500mcg once daily
		5mg once daily

We then used a Poisson model in order to describe the average number of daily doses of BOO medication prescribed each month, accounting for each of the covariates presented in Table 1, with additional spatial and temporal random effects. Possible interactions between the prescribing pattern of individual GP practices, or their geographical location, with the prescribed drug type were also investigated.

Equation 1 describes the model's functional form, while Table 3 summarises our choices in terms of spatial and temporal structure. Further details of the statistical analysis are provided as supplementary material.

$$n_{jti} \sim \text{Poisson}(\lambda_{jti})$$

$$\log(\lambda_{jti}) = \alpha + \alpha_{[i]} + \alpha_{[ji]} + \alpha_{[tji]} + \beta_1 \log(\text{list size}_{ti}) + \beta_2 \text{drug group} + \beta_3 \text{contract}_i + \beta_4 \text{dispensing}_i + \beta_5 \text{males 45p}_{ti} + \beta_6 \text{deprived 15}_{ti} + \beta_7 \text{remote}_{ti} \#(2)$$

where j (drug group), t (month), and i (each GP practice) are as described, and $\alpha_{[i]}$, $\alpha_{[ji]}$, $\alpha_{[tji]}$ denote the random effects, summarised in Table 3. A detailed discussion of the choice of the random components of the model is available in the technical supplement.

Table 3. Spatial and temporal random effects.

Parameter	Type	Short description
$\alpha_{[i]}$	Spatial	intrinsic Conditional Auto Regressive (iCAR)
$\alpha_{[ji]}$	Unstructured	Unstructured interaction between GP and drug type
$\alpha_{[tji]}$	Temporal	First-order Auto Regressive (AR1), grouped by health board and drug type

Computational analysis

All computational analyses were carried out in R 3.6.1 [14]. We estimated the model parameters within the Integrated Nested Laplace Approximation framework using the inla package [15].

Results:

We investigated the effects of each the available covariates (including GP patient list size; BOO drug group; whether the practice was GP run; whether the GP practice dispensed medication; proportion of males aged 45 years; higher proportion of socioeconomic deprivation; and remote/rural location) on the study outcome. Table 4 summarises the output of the Poisson regression estimates of each of the associated parameters. In a further analysis, we interpreted each of these parameters in terms of relative differences from the model average (with the exception of GP practice list size).

Table 4. Summary of estimated posterior distributions for fixed effects. This summarises the model estimates of the fixed effect, and the uncertainty surrounding the estimates.

	Mean	SD	2.5%	50%	97.5%	Mode
α – Intercept	-1.570	0.040	-1.648	-1.570	-1.492	-1.570
β_1 – log(GP patient list size)	0.915	0.002	0.911	0.915	0.919	0.915
β_2 – Drug group (5- α reductase inhibitors)	-0.625	0.017	-0.658	-0.625	-0.591	-0.625
β_3 – GP run practices	0.238	0.033	0.174	0.238	0.302	0.238
β_4 – Dispensing GP practice	-0.086	0.026	-0.138	-0.086	-0.035	-0.086
β_5 – Males aged ≥ 45 years	4.816	0.032	4.754	4.816	4.879	4.816
β_6 – Socially deprived area	0.017	0.007	0.003	0.017	0.030	0.017
β_7 – Remote/rural GP practice	0.002	>0.001	0.002	0.002	0.003	0.002

The GP practice patient list size was observed to have an effect consistent with an estimated increase of slightly less than one daily dose per month per additional patient (point estimate 0.915). As expected, the prescribed doses of the 5 – α reductase inhibitor drug group were observed to be on average less than the

prescribed doses of the $\alpha - 1$ blocker drug group. The estimated relative difference was calculated to be on average 45-48% fewer $5 - \alpha$ reductase inhibitor drug prescriptions than $\alpha - 1$ blocker drug prescriptions per month (point estimate 46%).

We observed that the nature of how the GP practices are individually run are associated with BOO drug-prescribing practice, with GP-run practices (rather than by direct Health Board-run practices) having larger volumes of these prescriptions. The model results are consistent with a 19-35% (point estimate 27%) increased number of monthly prescriptions for GP-run practices compared with Health Board-run practices, all else being equal. This is an interesting result, and to the best of our knowledge no rigorous research has been undertaken to investigate the role that how a GP practice is managed plays on the stability of GP provision of care and, in turn, on patient help seeking behaviours and clinical outcomes. Conversely, we observed that the small number of GP practices who run their own dispensary are associated with 3-13% (point estimate 8%) lower volumes of BOO drug prescriptions, compared to GP practices who do not, keeping all other variables constant. Practices that dispense tend to do so because there is no local community pharmacy, and one is needed for patient care. It is plausible that having a dispensing licence may reflect an aspect of remoteness that is not captured by the rurality measure we employ. We found the proportion of males aged ≥ 45 years in the GP practice patient list to be positively associated with the volume of BOO prescriptions, with an estimated average increase of 4.9% monthly prescriptions per percentage point. In contrast, the levels of socio-economic deprivation, and a remote/rural geographical location of each GP practice, were found to have a negligible association with prescribing practice.

Figure 1: Statistical model average number of daily doses of each BOO drug type prescribed per month, by individual Scottish Health Board and adjusted for GP practice patient roll size.

Next, we investigated the statistical model's interpolations according to Health Board and drug group (α -1 blocking drugs and 5- α reductase inhibitors) (**Figure 1**). This analysis highlighted a general increase in the volumes of prescriptions for these medications over the 4-year study period. Trends in prescribing were observed to be broadly similar across most Health Boards, with a less prominent increase in less populated areas, which may potentially be attributable to a more stable population structure over the 4-year period of observation, as well as unaccounted for differences in help seeking behaviours. Within most Health Boards the growth in prescriptions for each drug group were almost parallel during the four-year

219 observation period, suggesting consistency in terms of increased BOO drug
 220 prescribing. Additional observations included a marked shift in volumes of α -1
 221 blocking drug prescriptions in Lanarkshire between November 2016 and February
 222 2017, however no further specific information regarding this phenomenon was
 223 available within the publicly available dataset. In the absence of a reasonable
 224 explanation for this singular observation in this one Health Board, this has been
 225 treated as an artefact due to a change in data-recording.

226

227 **Figure 2:** Frequency histograms of the statistical model's exponentiated residuals for each Scottish
 228 Health Board. The vertical dashed line represents the null residual (value=1 on the exponentiated
 229 scale), and each small black square represents the average number of daily prescriptions of BOO
 230 drugs (combined α – 1 blockers and 5 – α reductase inhibitors) per month per individual anonymous
 231 GP practice within each Health Board. The boxplot below each histogram illustrates the same data

distribution (the white point marks the median, the thick line represents the usual box, and the thin line represents the whiskers). Ideally the exponentiated residuals for each GP practice would lie around the null residual (i.e. value=1), however the heterogeneity in prescribing practice is illustrated by increased spread to the left and right of the null residual. A shift of GP practice distributions to the right of the null residual, as seen in Health Boards such as Borders, Fife, Orkney, Shetland and Tayside, illustrates less prescribing of these medications than would be expected.

Next, we investigated how the statistical model residuals may provide insight into how BOO drug prescribing behaviour differed across Scotland during the 4-year study period. **Figure 2** illustrates histograms of exponentiated residuals for each individual Health Board across Scotland, where a reference value of $1 = e^0$ represents a null residual (i.e. there is no deviation from the model's predicted average). Each residual is specific to one individual anonymous GP practice. On an exponential scale, a value of 1 indicates a prescribing behaviour in line with the average as described by the statistical model across Scotland during the study period. A value below 1 indicates prescribing volumes higher than expected based on the model, whilst a value larger than 1 indicates prescribing volumes lower than expected. Asymmetry around the reference value of 1, and/or multiple modes of distribution, suggests a different behaviour of individual GP practices within a Health Board compared against the national average across Scotland.

Using this statistical approach, we generally observed consistency in the prescription of drugs for BOO across Health Boards in Scotland, with most distributions appearing to be approximately unimodal and symmetric around the null residual (i.e. the reference value of $1 = e^0$). However, some interesting patterns of prescribing can be observed, such as the reduced level of BOO drug prescribing in some individual Health Boards (most notably Borders, Forth Valley, Tayside, Orkney and Shetland) compared to the average prescribing rate across Scotland. The reasons for these

258 differences in prescribing pattern in these individual Health Boards are unclear and
259 require further investigation.

260 Next, we examined the BOO drug prescribing patterns of GP practices with the aim
261 of assessing and visualising possible spatial patterns. Once again using the model
262 residuals, it was possible to identify individual anonymous practices at the extremes
263 of the BOO prescribing distribution, and show their Health Board location on a map.
264 This approach can be useful in order to detect geographic clusters of similar
265 prescribing patterns, while accounting for temporal trends and other potential
266 confounding factors that are already included in the model. For example, the
267 policymaker might be interested in identifying clusters of GP practices where the
268 rates of prescribing are either very low or very high with respect to the national
269 average. We present the results of such analysis in **Figure 3** where, to preserve
270 anonymity of the individual practices, we have aggregated the information at the
271 Health Board level. We denote those GP practices with a model residual below the
272 2.5% percentile of the overall distribution of residuals as “high-volumes prescribers”,
273 and those above the 97.5% percentile as “low-volumes prescribers”. We stress that
274 high- and low- are with respect to the national average as described by the model
275 Moreover, the quantile thresholds are arbitrary and can be adjusted according to the
276 analytical need.

277

278 **Figure 3:** Maps of Scotland highlighting the Health Board locations of anonymous GP practices at the
 279 extremes of the distribution of BOO drug prescribing. The left panel shows the percentage of GP
 280 practices within each Health Board that have been identified (via model residuals) as being high in
 281 prescribing volumes with respect to the national average (i.e. model residuals <2.5% percentile).
 282 Similarly, the right panel shows the percentage of GP practices low in prescribing volumes with
 283 respect to the national average (i.e. model residuals >97.5% percentile).

284 We observed that Highland is the Health Board with the largest percentage (~9.5%)
 285 of GP practices that were identified as being in the upper tail of prescribing volumes
 286 (identified by model residuals <2.5% percentile), followed by Lothian (~5.3%),
 287 Dumfries and Galloway (~3.2%), Grampian (~2.9%), Forth Valley (~2%) and Greater
 288 Glasgow and Clyde (~1.7%). No high-volume prescribing GP practices were found
 289 within the remaining Health Boards. On the other hand, Tayside was identified as the
 290 Health Board with the largest percentage (~19%) of low-volume prescribers
 291 (identified by model residuals >97.5% percentile). Shetland (10%), Borders (~8.7%),
 292 Grampian (~5.7%), Highland (~1.1%), Lothian (~1%), and Greater Glasgow and
 293 Clyde (~0.9%) also contained GP practices that prescribed far below the national

294 average. The remaining Health Boards did not contain any low-volume prescribing
295 practices. The underlying reasons for these observations are currently unclear and
296 require further investigation.

297 Discussion

298 This study has investigated patterns of medical prescribing for the two most common
 299 classes of drug (i.e. α – 1 blockers and 5 – α reductase inhibitors) used to treat BOO
 300 in Scotland over a recent 4-year period (October 2015 - November 2019) using
 301 publicly available data from individual GP practices across all Health Boards. Using
 302 this approach we generated a study dataset by linking prescribing data to GP
 303 practice-specific information (such as their type of contract with NHS, and their
 304 licence to dispense) and summary characteristics of their patient populations (such
 305 as patient age, and GP practice-associated levels of socio-economic deprivation and
 306 rurality). This has enabled us to develop an improved understanding of patterns of
 307 prescribing of these medications across Scotland, and identify where prescription
 308 volumes may vary, having accounted for these variables.

309 A trend of increased BOO drug prescribing practice was observed throughout the 4-
 310 year observation window consistent with an ageing Scottish population, and perhaps
 311 also due to an increased awareness of male health issues amongst both patients
 312 and general practice teams, and increased referral of men to secondary care due to
 313 a raised PSA, which may indicate BPH as well as possible prostate cancer [16, 17].
 314 However, it would be interesting to understand more fully the reasons behind the
 315 observed increase in prescribing across all Scottish Health Boards, and the role that
 316 increased awareness and patient help seeking behaviour may play in this
 317 phenomenon. It may also be interesting to identify the relative contribution (or
 318 otherwise) made by increased referral to secondary care with suspected prostate
 319 cancer (as identified by a raised PSA), which might result in increased BOO/BPH
 320 prescribing as a secondary consequence of a raised PSA referral. A further
 321 possibility may be that an increased focus on cancer management, rather than BPH

surgery, may lead to an increase in medical drug use for BOO, rather than definitive intervention – this is speculative, but would be very interesting to investigate in future studies, particularly in order to investigate how this may vary geographically. Although it has been acknowledged that aspects regarding individual GP medical practices may potentially contribute to prostate health inequalities [18, 19], to our knowledge this is the first time that the particular characteristics of a GP practice (such as patient ages, GP-run practices, dispensing ability, socio-economic deprivation levels, and rurality) have been identified as being potential factors influencing BOO drug prescribing patterns. It was interesting to observe that whether a practice was Health Board or GP-run, and whether a dispensing pharmacy was present within the GP practice, was associated with higher and lower prescribing volumes respectively. While the individual characteristics of GP medical practices are known to differ by region [20], research accounting for these factors is relatively sparse; hence it is unclear why this difference exists.

This study has several limitations. Firstly, the available data only exists in the public domain at an aggregate (i.e. individual GP practice or patient list) level, and further information would be helpful in order to identify the reasons why prescribing practices vary at a more granular level (perhaps by associating the prescribing practice with the presence or absence of a GP with a particular interest in men's health issues, as an example). Secondly, the use of summary data regarding levels of socio-economic deprivation and rurality of patients reduces the accuracy with which one can estimate the shape of their association with outcome, with these factors likely to be important in terms of access to healthcare and prescribing. Similarly, not having information about specific GP practice catchment areas made it necessary to use an adjacency matrix based on postcodes, rather than actual

distances, resulting in a sub-optimal method of accounting for underlying spatial processes; furthermore, future work utilising anonymised individual-level patient data would also help to increase accuracy. Finally, it would be useful to analyse potential relationships between BOO drug prescribing patterns and longer-term outcomes from BOO in terms of clinical progression of this condition, such as need for future surgical intervention or treatment for BOO complications, such as acute urinary retention, and how they relate to investigation for suspected cancer or raised PSA. Such an analysis requires additional hospital data which in future work could be accessed via established high-quality data linkage systems in the Scottish National Safehaven.

It would also be interesting to understand the relative contribution of patient ageing to the rate of rise in BOO drugs prescription, and the degree to which other factors such as help-seeking behaviour and clinician awareness might be contributing to this rate of rise in prescription volumes. These possibilities require further investigation.

Nevertheless, despite these caveats and limitations, the analyses presented herein have identified interesting BOO medical prescribing trends across Scotland that require further investigation in future studies.

In addition to identifying influences from spatial, temporal, and socioeconomic factors in regards to volumes of prescription of BOO medications, our analysis suggests that other sources of variability might account for inequalities in prescribing practice. In recent decades a considerable amount of research has been undertaken in order to better understand complex health-related phenomena whose determinants might transcend socio-demographic factors, and can best be described by a unique regional culture or a strong 'social patterning' [21, 22]. Although at this stage it is

371 unclear what the remaining hidden determinants of the variations in BOO drug-
372 prescribing patterns may be, Scotland's cultural diversity as described in the wider
373 literature may constitute a potential explanation [9]. This warrants further
374 investigation in future research.

375 It would be interesting for future research to investigate trends and potential
376 inequalities regarding all prostate-related conditions (both benign and malignant)
377 over space and time in other settings and geographical locations. In particular, it
378 would be interesting to investigate whether the trends observed in Scotland may
379 similarly exist in other regions of the UK and Ireland, and if so, are variations
380 attributable to common factors such as remoteness/rurality and socio-economic
381 status. Further research to investigate medical practice phenomena as complex as
382 prescribing patterns using publicly available data may identify key limitations in
383 practice, and may inform data collection and data sharing in the future. In addition,
384 the general nature of the statistical modelling framework we have proposed in this
385 study may be extended to investigate other kinds of models, covariates, and medical
386 conditions in a range of future studies.

387 **Conclusions**

388 The volume of prescriptions of drugs for LUTS secondary to BOO has steadily
 389 increased across Scotland during a recent 4-year observation period, which may, at
 390 least in part, be attributable to an ageing population and increased diagnoses.
 391 Prescription volume for these medications is associated with various characteristics
 392 of the GP practice (such as type of contract and presence of a licence to dispense).
 393 However, some inequalities in prescribing across Health Boards in Scotland remain
 394 unexplained after accounting for GP practice- and patient-specific characteristics
 395 such as socio-economic deprivation and rurality, suggesting there may be other
 396 hitherto unknown determinants of BOO drug prescribing practice. Further research is
 397 warranted to understand these differences more fully.

Acknowledgements

The authors would like to acknowledge support and encouragement received by Prof Alan McNeill (NHS Scotland) and Prostate Scotland at the initial conception of this project.

References

- [1] European Association of Urology. EAU guidelines on non-neurogenic male LUTS. 2019.
- [2] Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 2014;30:170—6.
- [3] Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391:1023—75.
- [4] NHS National Services Scotland. Cancer waiting times. NHS National Services Scotland. 2019.
- [5] Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7984. doi: 10.1038/s41598-017-06628-8.
- [6] Bajic P, Montgomery J, Nelson M et al. (2020). 133 comparisons fo BPH medication prescribing among sexagenarians with Medicare an private insurance. J Sex Med. 2020; 17(1):37—38.

- 420 [7] Fu Y, Han S, Wang L, Geo W, Cao X, Wang J. Comparison of characteristics of
421 benign prostatic hyperplasia (BPH) patients treated with finasteride and alpha
422 blocker combination therapy verses alpha blocker monotherapy in China: An
423 analysis of electronic medical record data. Adv. Ther. 2018; 35:1191—1198.
- 424 [8] Moon HW, Yang JH, Choi JB, Bae WJ. Prescription pattern of alpha-blockers for
425 management of lower urinary tract symptoms/benign prostatic hyperplasia. Sci Rep.
426 2018; 8.
- 427 [9] Taulbut M, Walsh D, McCartney G et al. Spatial inequalities in life expectancy
428 within post-industrial regions of Europe: A cross-sectional observational study. BMI
429 Open. 2014; 4.
- 430 [10] Scottish Government. Scottish Index Of Multiple Deprivation. [online] available
431 at: <http://www.gov.scot/Topics/Statistics/SIMD> [accessed 9 Mar 2020].
- 432 [11] Scottish Government. Scottish Government Urban Rural Classification. [online]
433 available at:
434 <https://www2.gov.scot/Topics/Statistics/About/Methodology/UrbanRuralClassification>
435 [accessed 9 Mar 2020]
- 436 [12] National Institute for Health and Care Excellence. LUTS in men. National
437 Institute for Health and Care Excellence. 2019.
- 438 [13] McConnell JD, Roehrborn CG, Bautista OM et al. The Long-Term Effect of
439 Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of
440 Benign Prostatic Hyperplasia. Clinical Trial N Engl J Med. 2003 Dec 8;349(25):2387-
441 98. doi: 10.1056/NEJMoa030656.

- 442 [14] R Core Team. R: A language and environment for statistical computing. R
443 Foundation for Statistical Computing, Vienna, Austria 2019. URL [https://www.R-](https://www.R-project.org/)
444 [project.org/](https://www.R-project.org/).
- 445 [15] H. Rue, S. Martino, and N. Chopin. Approximate Bayesian inference for latent
446 Gaussian models using integrated nested Laplace approximations (with discussion).
447 Journal of the Royal Statistical Society, Series B. 2009; 71(2):319--392.
- 448 [16] National Records of Scotland. Mid-year population estimates Scotland, Mid-
449 2018. 2019.
- 450 [17] European Association of Urology. EAU guidelines on prostate cancer. 2019.
- 451 [18] Public Health England. Prostate cancer risk management programme: overview.
452 2016.
- 453 [19] Clements A, Bukach C, Rai T, Shine B, Austoker J, Watson E. What influences
454 men's decision to have a prostate-specific antigen test? A qualitative study. Family
455 Practice. 2007; 24.
- 456 [20] Burgess L. Primary Care in Scotland. The Scottish Parliament. 2018.
- 457 [21] Walsh D, McCartney G, Collins C, Taulbut M, Batty GD. History, politics and
458 vulnerability: explaining excess mortality in Scotland and Glasgow. Public Health.
459 2017; 151:1—12.
- 460 [22] Cowley J, Kiely J, Collins D. Unravelling the Glasgow effect: The relationship
461 between accumulative bio-psychosocial stress, stress reactivity and Scotland's
462 health problems. Prev. Med. Rep. 2016; 4:370-375.